[PDF][PDF] Pharmacoeconomic evaluation of the MF59-adjuvanted influenza vaccine in the elderly population in Italy

S Iannazzo - J Prev Med Hyg, 2011 - core.ac.uk
Introduction. Influenza vaccination has proven effective in the reduction of influenza-like
illness (ILI) cases and influenza-related hospitalizations, drug consumption, primary care …

[HTML][HTML] Safety and immunogenicity of influenza A (H5N1) vaccine stored up to twelve years in the National Pre-Pandemic Influenza Vaccine Stockpile (NPIVS)

CM Oshansky, J Zhou, Y Gao, JE Schweinle, K Biscardi… - Vaccine, 2019 - Elsevier
Background As part of the US Department of Health and Human Services (HHS) Pandemic
Influenza Plan preparedness and response strategy, the National Pre-Pandemic Influenza …

Safety and immunogenicity of MF59-adjuvanted cell culture–Derived A/H5N1 subunit influenza virus vaccine: dose-finding clinical trials in adults and the elderly

SE Frey, S Shakib, P Chanthavanich… - Open Forum …, 2019 - academic.oup.com
Abstract Background A/H5N1 influenza viruses have high pandemic potential; consequently,
vaccines need to be produced rapidly. MF59® adjuvant reduces the antigen required per …

A randomized clinical trial to identify the optimal antigen and MF59® adjuvant dose of a monovalent A/H1N1 pandemic influenza vaccine in healthy adult and elderly …

C Hatz, F von Sonnenburg, D Casula, M Lattanzi… - Vaccine, 2012 - Elsevier
BACKGROUND: Vaccines against pandemic A/H1N1 influenza are required to protect the
entire population. This dose range study aimed to identify priming antigen and adjuvant …

Receptor repertoires of murine follicular T helper cells reveal a high clonal overlap in separate lymph nodes in autoimmunity

M Niebuhr, J Belde, A Fähnrich, A Serge, M Irla… - Elife, 2021 - elifesciences.org
Follicular T helper cells (Tfh) are a specialized subset of CD4 effector T cells that are crucial
for germinal center (GC) reactions and for selecting B cells to undergo affinity maturation …

Immunogenicity and tolerability of an inactivated and adjuvanted pandemic H1N1 influenza vaccine, in HIV-1-infected patients

CL Tremblay, D Rouleau, C Fortin, E Toma, M Sylla… - Vaccine, 2011 - Elsevier
We evaluated the efficacy and tolerability of a single dose of the split virion AS03-adjuvanted
pandemic H1N1 influenza vaccine (A/California/7/2009) in 84 HIV-1 infected individuals …

Establishment of a novel safety assessment method for vaccine adjuvant development

E Sasaki, H Momose, Y Hiradate, T Mizukami… - Vaccine, 2018 - Elsevier
Vaccines effectively prevent infectious diseases. Many types of vaccines against various
pathogens that threaten humans are currently in widespread use. Recently, adjuvant …

Safety review: squalene and thimerosal in vaccines

M Montana, P Verhaeghe, C Ducros, T Terme… - Therapie, 2010 - journal-therapie.org
Few studies show the reluctance of the people to get vaccinated against A (H1N1) influenza
for fear of side effects of squalene (MF59, AS03, AF03) and thimerosal. The aim of this paper …

Identification of antigen and adjuvant doses resulting in optimal immunogenicity and antibody persistence up to 1 year after immunization with a pandemic A/H1N1 …

C Nassim, S Christensen, D Henry… - The Pediatric …, 2012 - journals.lww.com
Background: In the development of pediatric A/H1N1 influenza vaccines, this study was
performed to identify antigen and adjuvant doses providing optimal immunogenicity and …

The new H1N1 and HPV vaccines and old fears

A Balofsky, N Agmon-Levin… - Current opinion in …, 2010 - journals.lww.com
As more diseases are found to be preventable through vaccination, it is of great importance
to design better, more effective and better tolerated vaccines. This goal may be achieved …